Author

E. K. Kleczko

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:mouse· 5 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

R. A. Nemenoff· 5 shared A. Navarro· 3 shared A. T. Le· 3 shared E. T. Clambey· 3 shared L. E. Heasley· 3 shared T. K. Hinz· 3 shared T. T. Nguyen· 2 shared A. Goodspeed· 1 shared

Activity by Year

2022-2024 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

R. A. Nemenoff

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Inflammation promotes aging-associated oncogenesis in the lung.

C. Pham-Danis, S. B. Chia, H. A. Scarborough, E. Danis, T. Nemkov, E. K. Kleczko, A. Navarro, A. Goodspeed, E. A. Bonney, C. A. Dinarello, C. Marchetti, R. A. Nemenoff, K. A. Hansen, J. DeGregori

This study investigates how aging-related inflammation contributes to lung cancer development by analyzing gene expression data and using mouse models to assess the role of inflammation in oncogenesis.

bioRxiv · Mar 1, 2024Cancer Biology

Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response

L. E. Heasley, E. K. Kleczko, A. T. Le, T. K. Hinz, T. T. Nguyen, A. Navarro, C.-J. Hu, E. T. Clambey, D. T. Merrick, M. Weiser-Evans, R. A. Nemenoff

bioRxiv · Oct 26, 2022Cancer Biology

Evaluation of KRASG12C Inhibitor Responses in Novel Murine KRASG12C Lung Cancer Cell Line Models

D. J. Sisler, T. K. Hinz, A. T. Le, E. K. Kleczko, R. A. Nemenoff, L. E. Heasley

This paper develops three novel murine KRASG12C-driven lung cancer cell lines to evaluate responses to KRASG12C inhibitors and identify combination strategies for improved therapeutic outcomes.

bioRxiv · Aug 19, 2022Cancer Biology

Immune Checkpoint Activity Regulates Polycystic Kidney Disease Progression

E. K. Kleczko, D. T. Nguyen, K. H. Marsh, C. D. Bauer, A. S. Li, S. B. Furgeson, B. Y. Gitomer, M. B. Chonchol, E. T. Clambey, K. A. Zimmerman, R. A. Nemenoff, K. Hopp

This study investigates immune checkpoint activity in ADPKD, finding that dual checkpoint inhibition improves disease outcomes in adult-onset models.

bioRxiv · Apr 24, 2022Immunology

Adaptive immunity is required for durable responses to alectinib in murine models of EML4-ALK lung cancer

E. K. Kleczko, T. K. Hinz, T. T. Nguyen, N. J. Gurule, A. Navarro, A. T. Le, A. M. Johnson, J. Kwak, D. I. Polhac, E. T. Clambey, M. C. Weiser-Evans, T. Patil, E. L. Schenk, L. E. Heasley, R. A. Nemenoff

This paper shows that adaptive immunity enhances the durability of alectinib response in EML4-ALK lung cancer models, with CD8+ T cells playing a key role.

bioRxiv · Apr 14, 2022 · PreprintCancer Biology